Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The founder of the USC Annenberg Inclusion Initiative was recognized for her tireless work in equality and inclusion in ...